Background & Objective: Advances in public health and control of infectious diseases have led to increased number of elderly people in the world including Iran. Thus serious concerns exist in terms of age-related diseases . Consequently, Iran’s ministry of health has chosen “ageing and health” as the theme for 2012 along with WHO. Psychological disorders�are among the most prevalent diseases in elderly people. Recent studies suggest a two-way relationship between some psychological disorders and insomnia. Also there is evidence implying magnesium role in improvement of aforementioned disorders. The objective of this study was to determine the effects of dietary magnesium supplementation on mental health in insomniac elderly subjects.

  Methods: A double-blind randomized clinical trial was conducted on 46 insomniac elderly subjects randomly allocated into the magnesium or the placebo group, receiving daily for 8 weeks either 500 mg magnesium or a placebo, respectively. SCL-90-R and ISI questionnaires were conducted at baseline and at the end of the intervention period. Serum magnesium and cortisol levels were also determined in the patients. In addition, information was obtained on anthropometric confounding factors and daily intake of magnesium, calcium, potassium and caffeine using 24-hr dietary recall questionnaire for 3 days. The N4 and SPSS19 were used for data analysis.

  Results: No significant differences were observed in assessed variables between the two groups at baseline. As compared to the placebo group, in the experimental group, dietary magnesium supplementation brought about statistically significant decreases in GSI, PST, PSDI, ISI scores as well as somatization , anxiety, psychoticism , and depression symptoms and serum cortisol concentration. While the obsessive-compulsive , interpersonal sensitivity, hostility , phobic anxiety, paranoid ideation scores and serum magnesium concentration were not different between the experimental and the placebo groups.

  Conclusion: In this study dietary magnesium supplementation resulted in improvements in insomnia severity index and some indices of mental health.

  Background & objectives: This study evaluated the effect of intravenous magnesium sulphate on clinical improvement of the patients with acute stroke. There is a lot of information about the use of magnesium sulphate in different conditions of brain ischemia while the effect of magnesium sulphate as a neuroprotective agent has been demonstrated in focal and global brain ischemiain animal models. However, the effect of this agent is still unclear.

  Methods: 80 patients (47 % female and 53 % male) with acute ischemic stroke signs and symptoms, lasting less than 12 hours of ischemia, were included in the study. Patients were divided into two groups 40 patients received 4 g of MgSO ₄ over 15 minutes and then 16 g over the next 24 hours, and the other 40 patients received serum normal salin as the placebo.

  Results: The results showed that magnesium sulphate administrated group had better clinical improvement rate than control group. The number of patients with grade III decreased in magnesium received group and patients with grade II, I were increased. After 2 weeks, patients with Grade IIIdecreased to 12.5% and the patients with grade II and I increased to 50% and 37.5%, respectively(based on NIHSS score).

  Conclusion: According to this study,magnesiumsulphatecan be used as a neuroprotective agent in patients with acute stroke.

Background & objectives: Cardiac arrhythmia after CABG surgery is a common complication which results in other side effects. Therapeutic effect of prophylactic magnesium administration is controversial and there are many different ideas in this case. The aim of this study was to evaluate the therapeutic effects of magnesium in reducing cardiac arrhythmia after CABG.

Methods: The clinical trial enrolled 140 patients undergoing CABG. Based on the initial blood levels of magnesium, patients were divided into two groups, one group with low serum magnesium and the other group with normal one. The low serum magnesium group treated with magnesium preoperatively and had normal serum magnesium level before operation. Postoperatively, both groups were randomly divided into two sub-groups, one receiving 2 gr. of magnesium sulfate and the other group received placebo. Both groups monitored for occurrence of arrhythmia in the ICU – OH for 3 days. Data were analyzed with statistical methods. P value of <0.05 was considered statistically significant.

Results: The results showed that the occurrence of arrhythmia in any of the sub-groups was not significantly different from each other (p> 0.05). There was no significant relationship between blood levels of magnesium and arrhythmia at different days (p> 0.05).

Conclusions: Blood level of magnesium and prophylactic magnesium administration have not effect on reducing arrhythmia after CABG surgery. The highest incidence of arrhythmias happened in the hypomagnesium group without prophylaxis on the third day after surgery, but this difference was not statistically significant.